Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Tenaya Therapeutics’ major shareholder group, The Column Group affiliates, has updated its ownership and recent trading activity in the company’s common stock. Several Column Group funds now report no beneficial ownership, while TCG Opportunity III LP and related entities report beneficial ownership of 49,313,559 shares, representing 23.1% of the common stock based on 213,744,535 shares outstanding as of December 15, 2025.
The filing details a series of open-market sales in February 2026 by TCG III LP and TCG III-A LP. On February 20, 2026, they sold 245,965 and 277,769 shares, respectively, at a weighted-average price of $0.6149 per share. On February 23, they sold 143,709 and 162,291 shares at $0.5972 per share, and on February 24, they sold 309,228 and 349,212 shares at $0.6153 per share. On February 25, 2026, TCG III LP sold 1,649,281 shares and TCG III-A LP sold 1,862,545 shares at a weighted-average price of $0.5624 per share.
The filing notes warrants to purchase 53,571,426 additional shares of common stock held by TCG Opportunity III LP that are not exercisable within 60 days because of Beneficial Ownership Limitations. Managing partners Tim Kutzkey and Peter Svennilson are included as reporting persons and may be deemed to share voting, investment and dispositive power over the reported shares through the Column Group structure.
Tenaya Therapeutics’ major shareholder entities affiliated with The Column Group reported significant open‑market sales of common stock. Investment funds including The Column Group III, LP and related Opportunity funds sold a combined 4,170,266 shares of Tenaya common stock in indirect transactions.
The sales occurred on February 24 and 25 at weighted average prices of $0.6153 and $0.5624 per share, across multiple trades within disclosed price ranges. A related holding entry shows 49,313,559 shares of common stock held indirectly as of February 24, which reflects a large investment position by these affiliated funds.
COLUMN GROUP III, LP reported sales of common stock in TNYA-related transactions identified in a Form 144 notice. The filing lists multiple sales dated 02/10/2026 through 02/24/2026, including 1,904,115 shares on 02/11/2026 for $1,297,002.29 and 309,228 shares on 02/24/2026 for $190,267.99.
COLUMN GROUP III-A, LP reported proposed sales of common stock via Form 144 for Tenaya Therapeutics. The filings list multiple sale dates and share amounts with proceeds for each transaction.
Examples shown include sales of 2,151,458 shares on 02/11/2026 (proceeds $1,464,712.61) and 349,212 shares on 02/24/2026 (proceeds $214,870.14). The entries are presented as individual proposed sales by the reporting holder.
Column Group–affiliated investment funds, significant stockholders of Tenaya Therapeutics, reported open-market sales of an aggregate 829,734 shares of Common Stock on February 20 and 23. Reported weighted-average sale prices were about $0.61 per share, within disclosed ranges from $0.573 to $0.63.
The securities are held indirectly through entities including The Column Group III, LP, The Column Group III-A, LP and TCG Opportunity III LPPeter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.
Tenaya Therapeutics reported insider sales by Column Group III, LP in two transactions.
The filing lists a sale of 161,422 shares on 02/10/2026 for $131,736.49 and a sale of 1,905,115 shares on 02/11/2026 for $1,297,002.29.
Column Group III-A, LP filed a Form 144 reporting proposed sales of common stock in TENAYA THERAPEUTICS (TNYA), with recent sales disclosed. The filing lists prior transfers including 182,295 shares sold on 02/10/2026 and 2,151,458 shares sold on 02/11/2026.
The notice also lists earlier Series A purchases of 225,890 shares (07/31/2017) and 1,365,200 shares (12/20/2018) as origins of the holdings.
Higa Tomohiro reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 3,469 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 122,610 shares.
Ali Faraz reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 14,862 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 452,415 shares.
Tingley Whittemore reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 5,160 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 222,136 shares.